Literature DB >> 7520110

Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder.

M M Dwight, P E Keck, S P Stanton, S M Strakowski, S L McElroy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520110     DOI: 10.1016/s0140-6736(94)91952-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders.

Authors:  C A Zarate; M Vemuri; S Cavanagh; M Land
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.

Authors:  Neil M Richtand; Benjamin Taylor; Jeffrey A Welge; Rebecca Ahlbrand; Michelle M Ostrander; Jeffrey Burr; Scott Hayes; Lique M Coolen; Laurel M Pritchard; Aaron Logue; James P Herman; Robert K McNamara
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 4.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

5.  Treatment of bipolar mixed state with olanzapine.

Authors:  V Sharma; L Pistor
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

6.  Comparison of Risperidone and Olanzapine in Bipolar and Schizoaffective Disorders.

Authors:  Prakash S. Masand; Xiaohong Wang; Sanjay Gupta; Thomas L. Schwartz; Subhdeep Virk; Ahmad Hameed
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-04

Review 7.  Acute and long-term treatment of mania.

Authors:  Eduard Vieta; Jose Sanchez-Moreno
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.